<p>Shared tumor-associated antigen (TAA) vaccines are the legacy of several generations of cancer immunologists who have labored to bring them to patients with cancer to improve their disease outcome and eventually use them to prevent cancer. TAA vaccines failed as monotherapy but the development of checkpoint inhibitors and other reagents that can modify immunosuppressive tumor microenvironment, warrants their reassessment in…
Opportunity knocking: shared tumor-associated antigen vaccines against global cancer pandemic
Journal for ImmunoTherapy of Cancer | | Finn, O.
Topics: blood-cancer, cervical-cancer, sarcoma, immunotherapy, new-technology, research
Read the full article at Journal for ImmunoTherapy of Cancer